Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Image Quality and Activity Optimization in Oncologic F-18-FDG PET Using the Digital Biograph Vision PET/CT System
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.119.234351
document
The first Biograph Vision PET/CT system (Siemens Healthineers) was installed at the University Medical Center Groningen. Improved performance of this system could allow for a reduction in activity administration or scan duration. This study evaluated the effects of reduced scan duration in oncologic 18F-FDG PET imaging on quantitative and subjective imaging parameters and its influence on clinical image interpretation. Methods: Patients referred for a clinical PET/CT scan were enrolled in this study, received a weight-based 18F-FDG injected activity, and underwent list-mode PET acquisition at 180 s per bed...
Visual and quantitative evaluation of [F-18]FES and [F-18]FDHT PET in patients with metastatic breast cancer: an interobserver variability study
Published in: EJNMMI Research
Access to document
10.1186/s13550-020-00627-z
document
PURPOSE: Correct identification of tumour receptor status is important for treatment decisions in breast cancer. [18F]FES PET and [18F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR) status of individual lesions within a patient. Despite standardised analysis techniques, interobserver variability can significantly affect the interpretation of PET results and thus clinical applicability. The purpose of this study was to determine visual and quantitative interobserver variability of [18F]FES PET and [18F]FDHT PET interpretation in patients with metastatic breast cancer. METHODS: In this prospective, two-centre study,...
Lemonitsa H Mammatas, Clasina M Venema, Carolina P Schröder, Henrica C W de Vet, Michel van Kruchten, Andor W J M Glaudemans, Maqsood M Yaqub, Henk M W Verheul, Epie Boven, Bert van der Vegt, Erik F J de Vries, Elisabeth G E de Vries, Otto S Hoekstra, Geke A P Hospers, C Willemien Menke-van der Houven van Oordt
Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET
Published in: Molecular Imaging and Biology
Access to document
10.1007/s11307-020-01496-7
document
Purpose: Ovarian cancer (OC) leads to poor survival rates mainly due to late stage detection and innate or acquired resistance to chemotherapy. Thus, efforts have been made to exploit the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) to treat OC. However, patients eventually become resistant to these treatments as well. HER2 overexpression contributes to the acquired resistance to ER-targeted treatment. Trastuzumab treatment, on the other hand, can result in increased expression of ER, which, in turn, increases the sensitivity of the tumors towards anti-estrogen...
I F Antunes, G A P Hospers, J W A Sijbesma, A S Boerema, A van Waarde, A W J M Glaudemans, R A J O Dierckx, E G E de Vries, E F J de Vries
The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
Published in: Skeletal Radiology
Access to document
10.1007/s00256-020-03426-8
document
Purpose: To determine the value of prebiopsy 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) in discriminating malignant from benign vertebral bone lesions. Materials and methods: This retrospective study included 53 patients with 55 vertebral bone lesions that underwent FDG-PET/CT before CT-guided biopsy. Pathologic examination of the biopsy sample and a minimum follow-up of 1 year were used as reference standard. Results: Sensitivity, specificity, positive predictive value, and negative predictive value of visual FDG-PET analysis (with lesion FDG uptake higher than liver FDG uptake as threshold for malignancy) in discriminating...
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization
Published in: Journal of Nuclear Cardiology
Access to document
10.1007/s12350-019-01761-5
document
Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.
Sharmila Dorbala, Yukio Ando, Sabahat Bokhari, Angela Dispenzieri, Rodney H Falk, Victor A Ferrari, Marianna Fontana, Olivier Gheysens, Julian D Gillmore, Andor W J M Glaudemans, Mazen A Hanna, Bouke P C Hazenberg, Arnt V Kristen, Raymond Y Kwong, Mathew S Maurer, Giampaolo Merlini, Edward J Miller, James C Moon, Venkatesh L Murthy, C Cristina QuartaClaudio Rapezzi, Frederick L Ruberg, Sanjiv J Shah, Riemer H J A Slart, Hein J Verberne, Jamieson M Bourque